Next, we employed NBSBM to predict the estrogen receptor-positive breast cancer patients’ response to Tamoxifen treatment, using a previously reconstructed estrogen receptor-positive breast cancer-specific network [16] and the gene expression data of those 103 breast cancer patients. This evidence concerns the gene ESR1 and breast cancer.